243 Users Online
A Detailed Analysis of the Cancer Tissue Diagnostics Market Based on Spotlight on Oncology, An Astonishing Rise in Cancer Prevalence, and Technological Advancements
The global cancer tissue diagnostics market is forecast to expand at a CAGR of 6.9% and thereby increase from a value of US$6.9 Bn in 2023, to US$11.1 Bn by the end of 2030.
Cancer Tissue Diagnostics Market Size (2023E)
Projected Market Value (2030F)
Global Market Growth Rate (2023 to 2030)
Historical Market Growth Rate (2018 to 2022)
Tissue diagnostics prove to be a highly reliable method for cancer diagnosis and treatment planning, capturing the biological context of cancer cells. The increasing demand and anticipated future growth in the cancer tissue diagnostics market can be attributed to the surging rates of cancer.
Various factors contribute to this growth, such as the escalating incidence of diverse types of cancers, a heightened focus on preventive healthcare, the broader applications of digital pathology, intensified cancer awareness initiatives, advancements in more effective diagnostic and monitoring tools, and an overall enhancement in diagnostic accuracy. These factors collectively contribute to the positive outlook for the global cancer tissue diagnostics industry.
Growing Burden of Cancers, and Aging Population
Tissue-based diagnostics play a pivotal role in cancer diagnosis within the field of oncology. The escalating cancer burden is anticipated to drive the demand for tissue diagnostics. For instance, according to a report from Macmillan Cancer Support in October 2022, the incidence of cancer in the United Kingdom (UK) was on the rise, with the number of individuals living with cancer projected to increase from 3.5 million in 2025 to 4 million by 2030. Over the last decade, cancer incidence in the UK has surged by approximately 19%, attributed to factors such as a growing and aging population, increased cancer awareness, and enhancements in the country's cancer diagnosis infrastructure.
In France, the Institute National Du Cancer's July 2023 update predicts over 433 thousand new cancer cases in 2023, with 57% affecting men and 43% women. The three most prevalent forms of cancer in men are expected to be prostate, lung, and colorectal, while in women, breast cancer will be the most common, followed by colorectal and lung cancer. The rising prevalence of cancer is thus anticipated to fuel the demand for tissue diagnostics instruments and reagents.
Understaffing, and Retirement Rates
Histology laboratories are vital to the accuracy, safety, and speed of sickness diagnosis. Histology is needed to understand illness causes and how therapies operate. Cancer rates increase the requirement for clinical histology services. 80% of cancer diagnostics involve histology. These facilities are understaffed. According to Inside Lab 2020, only 3% of UK diagnostic labs had enough staff to perform diagnostic and regular tasks, including reporting. Germany has the lowest proportion of pathologists to practicing physicians in Europe, the US, and Canada. Germany's ratio is 1:200, while the US, and Canada have 1:70. PubMed 2020 As many histologists retire, few are entering the field. Histology labs are struggling to process more samples with fewer workers. This could limit the cancer tissue diagnostics industry's growth.
Increasing Adoption of Refurbished Diagnostic Imaging Systems
In developing countries, numerous hospitals face financial challenges that hinder them from investing in diagnostic imaging equipment due to factors like higher costs, inadequate reimbursement rates, and budget constraints. However, given the substantial demand for diagnostic imaging procedures in these regions, hospitals with limited financial resources often prefer opting for refurbished imaging systems. Refurbished systems come at a lower price point, typically ranging from 40% to 60% of the original equipment cost, making them a more accessible alternative.
Recognizing this trend, several market leaders are actively endorsing refurbished devices through diverse programs. Examples include Siemens' Medical Proven Excellence Program, GE Healthcare's Gold Seal Program, and Philips' Diamond Select Program, all of which are noteworthy global initiatives aimed at promoting the use of refurbished diagnostic imaging systems.
Introduction of Novel Diagnostic Biomarkers
The enhanced comprehension of specific cancer biomarkers presents a significant commercial opportunity for the enhanced treatment of cancer patients, facilitated by advancements in detection technology and equipment. Technological progress in biotechnology has enabled the identification of potential cancer biomarkers, and certain biomarkers have already been commercialized. Consequently, the introduction of new diagnostic biomarkers is generating lucrative prospects for the expansion of the cancer diagnostics market.
The cancer tissue diagnostics market is anticipated to undergo substantial expansion and change. In efforts to detect cancer at its early stages and reduce mortality rates, developed countries' governments and primary care physicians are advocating cancer screening tests for individuals. The US Preventive Services Task Force (USPSTF) suggests colorectal cancer screening for individuals aged 50 to 75 in the US, aiming to prevent disease incidence and facilitate early-stage treatment. Similarly, Canada has established guidelines recommending biennial colorectal cancer screening for individuals between the ages of 50 and 74.
Several factors, including the Rising prevalence of cancers and growing investment in healthcare facilities, all contribute to the dynamic and rapid expansion of the global Cancer Tissue Diagnostics market. Abbott Laboratories, F.Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Ventana Medical Systems, Inc., and Bio Rad Laboratories Inc. are market leaders in the manufacturing sector.
The countries of Germany, Japan, China, France, and the US are significant producers of various goods. Stakeholders in the US business sector are expanding their efforts due to an increase in cancer diagnoses and advancements in diagnostic tools. According to the cancer tissue diagnostics market report, the average likelihood of a woman in the United States developing breast cancer during her lifetime is approximately 13%. In 2018 alone, an estimated 234,030 new cases of lung cancer were identified, and there are currently 541,000 Americans who have received a lung cancer diagnosis at some point.
Several corporations are allocating resources towards expanding their capacity to satisfy the increasing need for healthcare infrastructure. It is anticipated that these expansions will substantially alter the dynamics of the market, resulting in heightened competition, reduced prices, and an influx of innovative products.
Which Test Type is Likely to Lead the Way?
Breast Cancer Represents the Topmost Segment
Breast cancer encompasses a range of breast tumor subtypes with distinct molecular and cellular origins, as well as varied clinical behavior. This segment plays a significant role in the overall market, and the prevalence of breast cancer is expected to persist as a dominant trend throughout the forecast period. The global burden of breast cancer continues to rise, exemplified by statistics such as the American Cancer Society's 2023 report estimating that approximately 13% of women in the United States will develop invasive breast cancer during their lifetime. According to the same source, breast cancer remains one of the most frequently diagnosed cancers in the United States, with an anticipated 300.6 thousand new cases in 2023, compared to 290.6 thousand cases in 2022.
Which of the in-Situ Hybridization (ISH) Tests Spearhead?
The Breast Cancer Segment Strengthens its Footprint Further, with Breast Cancer Diagnosis Initiatives
As per the December 2022 report by the Italian Association of Medical Oncology (AIOM), the Italian Association of Cancer Registries (AIRTum), and other entities, Italy recorded over 391 thousand new cases of cancer in 2022. Among these, breast cancer emerged as the most prevalent form, followed by colorectal, lung, prostate, and bladder cancer. The rising incidence of breast cancer is anticipated to fuel the need for sophisticated diagnostic tools, such as tissue diagnostics, thereby contributing to the growth of this market segment.
Top Regional Markets
North America’s Market on an Incessant Growth Trail as Cancer Cases Continue to Soar
Cancer stands as one of the most prevalent chronic diseases in North America, with a yearly increase in cancer incidence. This escalating trend in cancer cases is anticipated to drive the demand for advanced diagnostic products, including instruments and reagents, thereby contributing to the heightened demand for tissue diagnostic products throughout the forecast period. For instance, as indicated in the American Cancer Society's (ACS) reports for 2021 and 2023, the estimated incidence of cancer cases witnessed an uptick from 1.91 million in 2021 to 1.96 million in 2023, reflecting a rise of over 60 thousand cases in just two years. This data underscores the rapid increase in cancer incidence in the country. Projections indicate a continued rise in incidence over the forecast period, underscoring the need for precise diagnostic products to facilitate early-stage therapies.
Asia Pacific Gears up for Solid Expansion Through 2030 and Beyond
The expansion of the Asia Pacific market is driven by factors such as the increasing prevalence of cancer, enhancements in healthcare services, growing healthcare expenditures, and a rise in early cancer screening initiatives. In China alone, approximately 4,285,033 new cases of cancer were reported in 2020, comprising 2,366,010 male and 1,919,023 female cases. Data reveals that the crude and age-standardized death rates for men were 201.3 and 130.1 per 100,000, respectively. These statistics suggest that China is poised to remain a focal point for the cancer tissue diagnostics industry.
Prominent organizations, including Abbott Laboratories, F. Hoffmann-La Roche Ltd., and Thermo Fisher Scientific Inc., are at the vanguard of this sector, providing inventive solutions by capitalizing on their technological prowess and vast experience in the healthcare industry. Prominent companies like Abbott Laboratories and F. Hoffmann are placing significant emphasis on advancing diagnostic tests designed to offer crucial information. Notably, FISH tests play a vital role in diagnosing solid neoplasms and biomarker hematologic.
Furthermore, they are being applied in the realm of personalized medicine. Prominent companies within the cancer tissue diagnostics sector are increasingly recognizing the rising demand for their products in the field of digital pathology. This is anticipated to drive the formation of strategic partnerships in the global cancer tissue diagnostics industry, fostering collaborations between technology providers and digital pathology platforms shortly.
To distinguish themselves in this highly competitive market, these businesses strive to differentiate their products. They achieve this by providing distinctive attributes, such as precision in tissue analysis, innovative biomarker identification, and comprehensive pathology solutions.
New Product Launch
In June 2020, F. Hoffmann-La Roche AG, the Swiss pharmaceutical and diagnostics conglomerate, introduced its state-of-the-art, fully automated digital pathology platform, uPath PD-L1 (SP263), with CE-IVD certification. This platform is designed for non-small cell lung cancer (NSCLC) research.
Market Impact: With its advanced digital pathology capabilities, this cutting-edge technology makes tissue diagnostics for non-small cell lung cancer (NSCLC) more accurate and effective. Its automation features improve process effectiveness and may shorten the time it takes to get diagnostic results. As a result, researchers and medical professionals may gain from faster and more accurate cancer tissue analysis, which could result in more efficient treatment plans and personalized medicine strategies. Additionally, the release of such cutting-edge technologies frequently sparks rivalry and motivates other industry participants to create, which eventually helps the cancer tissue diagnostics market expand and grow.
In June 2022, Roche unveiled the release of VENTANA DP 600, a state-of-the-art slide scanner representing the next generation in pathology technology. This advanced slide scanner, characterized by its high capacity, offers pathology laboratories enhanced workflow flexibility and user-friendly operations. Simultaneously, it ensures the production of stained histology slides featuring exceptional image quality derived from tissue samples.
Market Impact: With its advanced capabilities and improved workflow flexibility, the next-generation slide scanner makes pathology labs more user-friendly. The scanner's high-capacity design makes it possible to handle a huge amount of tissue samples more efficiently, which helps to streamline the diagnostic procedure. It is anticipated that the overall effectiveness and speed of cancer tissue diagnostics will increase as more laboratories embrace and integrate this cutting-edge technology. Faster turnaround times for diagnostic results may arise from this, allowing for prompt treatment decisions and maybe bettering patient outcomes.
2023 to 2030
Historical Data Available for
2018 to 2022
US$ Million for Value
Key Regions Covered
Key Countries Covered
Key Market Segments Covered
Key Companies Profiled
Customization & Pricing
Available upon request
By Test Type:
By In Situ Hybridization (ISH) Test: